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Abstract
Background: Skull base chordomas are rare and heterogeneously behaving tumors. Though still classified as
benign they can grow rapidly, are locally aggressive, and have the potential to metastasize. To adapt the treatment
to the specific needs of patients at higher risk of recurrence, a pre-proton therapy prognostic grading system would
be useful. The aim of this retrospective analysis is to assess prognostic factors and the “Sekhar Grading System for
Cranial Chordomas” (SGSCC) by evaluating the larger cohort of patients treated at our institution as to determine its
reproducibility and ultimately to ensure more risk adapted local treatments for these challenging tumors.
Methods: We analyzed 142 patients treated for skull base chordomas between 2004 and 2016. We focused the
analysis on the 5 criteria proposed for the SGSCC (tumor size, number of anatomic regions and vessels involved,
intradural invasion, as well as recurrence after prior treatment) and classified our patients according to their score
(based on the above mentioned criteria) into three prognostic groups, low-risk, intermediate-risk and high-risk. The
three groups were then analyzed in regards of local control, local recurrence-free survival and overall survival.
Results: The median follow up was 52 months (range, 3–152). We observed 34 (24%) patients with a local
recurrence, resulting in a local control of 75% at 5 years. Overall survival was 83% at 5 years, 12 (9%) patients had
died due to local progression. When split into the three prognostic groups according to the SGSCC the observed
local control was 90, 72 and 64% (p = 0.07) in the low-, intermediate- and high-risk group, respectively. A similar
correlation was observed for local recurrence-free survival with 93, 89 and 66% (p = 0.05) and for overall survival
with 89, 83 and 76% (p = 0.65) for the same prognostic groups.
Conclusions: After splitting our patient cohort into the three SGSCC risk groups, we found a trend towards better
outcome for those patients with lower as opposed to higher scores. These results suggest that this prognostic
grading system published by Sekhar et al. could be integrated in the management decision-tree for patients with
skull base chordoma.
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Background
Chordomas are very rare tumors with an incidence of
0.08–0.1/100000 per year, making up 1–4% of all bone
tumors [1–3]. Their cells derive from remnants of the em-
bryonal notochord, occurring most commonly in the sacral
region (50–60%) followed by the skull base (25–30%) [3, 4].
Although they are slow growing and histologically consid-
ered low-grade tumors that rarely metastasize, they are lo-
cally aggressive with a high local recurrence rate, causing
severe morbidity and even death due to the proximity to
critical structures such as nerves or – as in the case of skull
base chordomas (SBC) – the brain stem. This means that
local treatment is key, with maximally safe resection
followed by radiation treatment as the standard of care
[5–8]. However, due to the location of these tumors
optimal aggressive local treatment, be it with surgery or
radiation therapy, is also challenging, resulting in sub-
optimal local control in a substantial number of pa-
tients. Aiming at treatment improvement, many recent
studies evaluated the prognostic factors of patients with
SBC, such as tumor size, location and extent of surgery,
showing a correlation between these factors and local
recurrence rates as well as survival [9–12]. Even though
prognostic factors could be identified, only one com-
prehensive score had been developed implementing
these factors in the pre-treatment setting so far [13] –
until Sekhar et al. published their work (the “Sekhar
Grading System for Cranial Chordomas”; SGSCC) in
2017 classifying patients with SBC into low, intermedi-
ate or high-risk groups [14]. As that aforementioned
retrospective analysis was performed on a small cohort
of only 42 patients, an additional analysis of this score
applied on a larger cohort is the goal of this work. Add-
itionally, we also sought to assess which variables pre-
dicted for SBC patients’ outcome after pencil beam
scanning proton therapy (PBS-PT).
Methods
Patients
This retrospective analysis was performed at the center for
proton therapy of Paul Scherrer Institute (PSI) in Villigen,
Switzerland. Patients (adults and children alike) treated
with curative intent for histologically proven SBC with
PBS-PT between 1998 and 2016 were included. The pres-
ence of metastatic disease was an exclusion criterion for
this study. One hundred and ninety-three such patients
were identified. Forty-eight (25%) patients were excluded
because of lack of pre-operative magnetic resonance im-
aging (MRI) assessable with full T1/T2 sequences in our
Picture Archiving and Communication System. Three (2%)
other patients were excluded because they did not consent
to the use of their data for publishing purposes. As such,
142 (74%) of the 193 identified patients were eligible for
analysis. The patient’s medical records were reviewed for
patient characteristics, tumor features, treatment parame-
ters and clinical outcomes. In regards to tumor resection
before PBS-PT gross total resection (GTR) was defined as
resection of all visible tumor under the surgical microscope
and was achieved in 19 (13%) patients. In 118 (83%) pa-
tients only sub-total resection (STR) was achieved, but re-
section adequate to proceed with PBS-PT. Five (4%)
patients had a biopsy only. All patient characteristics are
detailed in Table 1. This analysis was approved by the
Northwest and Central Switzerland Ethics Committee
(EKNZ 2018–00621) and conducted in accordance with in-
stitutional guidelines and the principles of the Declaration
of Helsinki and its subsequent amendments [15].
Sekhar grading system for cranial Chordomas (SGSCC)
For the purpose of this analysis, we computed the
SGSCC score according to the paper by Sekhar et al.
[14], as a function of tumor size and site, vascular in-
volvement, intradural invasion, and recurrence of the
tumor after prior treatment (Table 2). All these variables
refer to the state of the SBC directly before the upfront
treatment modality (surgery and/or PBS-PT).
For tumor size we applied the formula for tumor
equivalent diameter (TED) Dmean = (a*b*c)
1/3. We scored
the 5 criteria as suggested in the original article and
sorted the patients according to their score. Scores (ran-
ging from 2 to 25 points) were computed into three
prognostic groups (2–7 points low-risk, 8–12 points
intermediate-risk and 13–25 points high-risk). Forty three
(30%) SBC patients were scored not only by a radiation
oncologist but also independently by a neuro-radiologist,
so as to assess the inter-variability of the evaluators. The
SGSCC scores (median: 10 vs. 9; range: 4–15 vs. 4–16)
and grouping were not significantly different between the
neuro-radiologist and radiation oncologist (p = 0.43). As
such, the rest of the cohort was scored by the radiation
oncologist only.
Pencil beam scanning proton therapy
All patients were treated with PBS-PT using the 250 or
590MeV cyclotrons at PSI, computed with a 3D-
treatment planning system (PSI-Plan) as described by
Weber et al. [9]. Six (4%) patients were also treated with
photon therapy to a median dose of 12.0 Gy (range, 2.0–
59.4). The median total delivered total dose was 74.0
GyRBE (range, 72.6–80.0). Fractional doses ranged from
1.8 to 2.5 GyRBE with most patients receiving 2.0
GyRBE per fraction. Single-field uniform dose (SFUD)
plans and intensity modulated proton therapy (IMPT)
plans were used sequentially at PSI.
Statistical analysis
Time to death and local recurrence (LR) or distant re-
currence (DR) were determined from the first day of
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proton therapy. The first imaging showing LR or DR
was the event for local control (LC) and distant control
(DC) respectively, whereas death was the event for over-
all survival (OS). The first imaging showing LR, or pa-
tient death due to local tumor progression were the
events for local recurrence-free survival (LRFS). Survival
rates were calculated using the Kaplan-Meier actuarial
method. The log-rank test was used to compare different
functions for LC and survival. Two-sided p-values were
considered statistically significant at p = < 0.05. JMP
(version 12.2.0; SAS Institute Inc.) was used for statis-
tical analyses.
Results
After a median follow-up time of 52 months (range, 3–
152), 35 (25%) failures were observed. Of those 35 fail-
ures, 30 were isolated local recurrences, 4 patients had
local and distant failures and one patient presented with
an isolated distant failure (Table 3).
At 5 years LC was 75% (95% CI 67–82), and the LRFS
was 70% (95% CI 60–78). Twenty-one (14.8%) patients
had died during a period of 3 to 95 months (median, 43
Table 2 Criteria for the SGSCC
Tumor size (TED) 0–4 points
< 2 cm 1
2 cm to 3.9 cm 2
4 cm to 5.9 cm 3
> 5.9 cm 4
Tumor sites 1 point each
Upper clivus
Middle clivus
Lower clivus
Left petrous bone
Right petrous bone
Left cavernous sinus
Right cavernous sinus
C1/2/3 left
C1/2/3 right
Vascular involvement 1 point each
Left carotid artery
Right carotid artery
Basilar artery
Left vertebral artery
Right vertebral artery
Intradural invasion 0–2 points
No 0
Slight 1
With brainstem compression 2
Recurrence after prior treatment 0–5 points
No 0
After surgery 2
After RT 3
After Surgery and RT 5
TED tumor equivalent diameter, C1/2/3 cervical vertebrae 1–3, RT radiotherapy
Table 1 Patients’ and disease characteristics (n = 142)
Age at diagnosis median (range)
42 (1–79)
Gender n (%)
Female 66 (46)
Male 76 (53)
Histology n (%)
Non-chondroid 136 (96)
Chondroid 6 (4)
Number of surgeries (biopsies included) n (%)
1 75 (53)
2 46 (32)
> 2 21 (15)
Maximal extent of resection n (%)
Gross total resection 19 (13)
Subtotal resection 118 (83)
Biopsy 5 (4)
Surgical complications n (%)
No 88 (62)
Yes 54 (38)
Brainstem compression before PT n (%)
No 105 (74)
Abuttment 27 (19)
Yes 10 (7)
Optic pathway compression before PT n (%)
No 121 (85)
Abuttment 15 (11)
Yes 6 (4)
Any compression/abuttment before PT n (%)
No 88 (62)
Yes 54 (38)
Delivered dose in GyRBE median (range)
Total dose 74.0 (72.6–80.0)
Single dose 2.0 (1.8–2.5)
GTV in cc median (range)
26.3 (0.0–130.4)
PT for recurrent disease n (%)
No 120 (85)
Yes 22 (15)
PT proton therapy, GyRBE relative biological effective dose in gray, GTV gross
tumor volume, cc cm3
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months) after PBS-PT, resulting in a 5-year OS of 83%
(95% CI 73–88). Cause of death was in 57% of cases
(n = 12) local tumor progression. Other causes were car-
diovascular disease (n = 3; 14%), infections (n = 2; 10%),
second malignancies (n = 3; 14%) and suicide (n = 1; 5%).
Analyzing the patient data according to the SGSCC
(Table 4) we found that 8 patients (6%) had tumors
smaller than 2 cm, 81 patients (57%) between 2 and 3.9
cm, 51 (36%) between 4 and 5.9 cm and 2 patients (1%)
had tumors larger than 6 cm. In 74 cases (52%) the SBC
was located in three or fewer sites of the skull base, and
73 patients (51%) showed vascular involvement. Intra-
dural invasion was present in 124 (87%) patients. Only a
minority of patients (n = 21; 15%) was treated for a
recurrence after prior treatment, and just one of them
had received radiotherapy before. The low-risk group
consisted of 40 patients with a score < 8 (28%), 83 pa-
tients with a score of 8 to 12 fell into the intermediate-
risk group (59%), and the high-risk group was made up
of 19 patients with a score > 12 (13%).
At 5 years, we estimated a LC of 90, 72 and 64% (p =
0.07; Fig. 1), a LRFS of 93, 89 and 66% (p = 0.05) and an
OS of 89, 83 and 76% (p = 0.65) for the low-, intermedi-
ate- and high-risk group, respectively. The difference in
LC was significant (p = 0.04) after univariable analysis
(Table 5), comparing the low-risk group (score of < 8) to
the other two (score ≥ 8).
In univariable analysis we also looked at individual
non-SGSCC prognostic factors. Patients who had re-
ceived PT for recurrent disease after prior treatment had
a significantly worse LC (p = < 0.01). Regarding surgical
intervention, patients who had been operated on twice
or less had not only a better LC (p = 0.01) but also a bet-
ter OS (p = < 0.01) than patients with more than two
surgeries. There was no significant difference regarding
LC or OS when looking at the maximum extent of the
surgery (GTR vs. STR or biopsy), whereas surgical com-
plications were an indicator for worse OS (p = 0.01).
Patients with > 40 cc of residual disease before PT
(measured as gross tumor volume (GTV) used for plan-
ning) had a worse LC (p = 0.01) and OS (p = < 0.01)
compared to patients with ≤40 cc. There was also a sig-
nificant negative impact on LC for patients with tumor
compression of the brainstem and/or optic apparatus be-
fore PT (p = < 0.01) without effect on OS.
Discussion
Outcome
Due to their locally aggressive behavior and possible
proximity to critical structures such as the brainstem,
the prognosis of skull base chordomas patients is medi-
ocre at best with a median survival of 7.7 years described
in the literature [1]. In this retrospective analysis the 5-
year LC rate was 75% and the 5-year OS was 83%, which
is in line with our last publication on chordoma treated
with PBS PT [9]. As patients can experience substantial
treatment related toxicity, be it after surgery and/or
radiotherapy, it is of paramount importance to tailor the
treatment intensity with the patient’s prognosis, to
optimize the therapeutic ratio. Ideally, one should be
able to tailor the adjuvant PT to a SBC patients after
surgery, those deemed at high risk of recurrence man-
aged by a dose-escalation paradigm (i.e. > 74 GyRBE)
with or without targeted agents and those at lower risk
treated with more conventional radiation doses (i.e. ≤ 74
GyRBE) thus decreasing somewhat the likelihood of
radiation-induced adverse events [16, 17].
Table 3 Failures
n (%)
Only local failure 30 (21)
Only distant failure 1 (1)
Both local and distant failure 4 (3)
Total 35 (25)
Table 4 Patients according to SGSCC
Tumor size (TED) n (%)
< 2 cm 8 (6)
2 cm to 3.9 cm 81 (57)
4 cm to 5.9 cm 51 (36)
> 5.9 cm 2 (1)
Tumor sites n (%)
≤ 3 74 (52)
> 3 68 (48)
Vascular involvement n (%)
≤ 1 73 (51)
> 1 69 (49)
Intradural invasion n (%)
No 18 (13)
Slight 38 (27)
With brainstem compression 86 (60)
Recurrence after prior treatment n (%)
No 121 (85)
After surgery 20 (14)
After RT 0 (0)
After Surgery and RT 1 (1)
Total Score n (%)
< 8 40 (28)
8 to 12 83 (59)
> 12 19 (13)
SGSCC Sekhar Grading System for Cranial Chordoma, TED tumor equivalent
diameter, RT radiotherapy
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Prognostic factors
In order to identify patients at higher risk for recurrence
many prognostic factors have been described in recent
literature, not limited to but including pre-PBS-PT size
of tumor, compression of organs at risk (OAR), initial
tumor size at diagnosis, the need for a second course of
radiation treatment or non-GTR [9–11, 18]. The meta-
analysis by Zou et al. [12] gives a very comprehensive
overview of many prognostic factors including an array
of molecular biomarkers, and whether they are associ-
ated with the outcome in patients with SBC. What is
currently missing is a comprehensive scoring system,
which would include all above-mentioned factors and
could be used in the pre-treatment setting – to guide
treatment according to the patient’s risk for recurrence
but also to manage the tumor surveillance at follow-up.
Most local failures occur within 2–3 years after treat-
ment [19]. However, there are some patients who pro-
gress or develop recurrences later, as was the case for 7
(5%) patients in this cohort who had a local failure later
than 5 years after treatment.
Previous scoring systems
Before Sekhar et al. devised their SGSCC, only one scor-
ing system had been developed. In 2016, Jun-Peng et al.
published the proposal and validation of the “Basic Pro-
gression Scoring System for Patients with Skull Base
Chordoma” (BPSC) [13]. Retrospectively, 170 patients
were separated in a training and validation set. Using the
training set, 11 factors were identified that could have an
impact on progression. Of those, 5 were significant on
multivariate analysis and put in the BPSC – age (< 22 vs.
≥ 22 years), treatment history (previous surgery or radio-
therapy), pre-treatment KPS (< 70 vs. ≥ 70), pathology
(classical vs. chondroid) and MRI features (ratio of the
mean signal intensity of tumor to the mean signal inten-
sity of surrounding brainstem). Based on a total score
ranging from 0 to 5 the patients were distributed into
three groups, showing a significant difference regarding
progression-free survival (PFS). The score was then suc-
cessfully validated on the second set. To our knowledge,
this score never really found its way into clinical prac-
tice. Although successfully validated for PFS, it lacks tan-
gible criteria that can actually be taken into account
before and during treatment (such as for example tumor
size, compression of OAR or vascular involvement). The
factors for the BPSC are more general such as age, “Kar-
nofsky Performance Status” (KPS) or previous treatment.
Therefore, it gives the health professionals an overall
idea of prognosis and can be helpful for follow-up, but
does not specifically tell us how to improve and guide
treatment itself for an individual SBC patients.
SGSCC scoring system
As described above, in 2017, Sekhar et al. proposed the
SGSCC, a pre-operative scoring system based on a small
cohort of 42 patients. Our attempt to assess it using our
cohort of 142 patients treated with PBS-PT demon-
strated the complexity of factors affecting the outcome
of patients with this tumor. On univariable analysis there
was a significant benefit regarding LC for patients in the
low-risk group compared to the other two groups
(Fig. 1), suggesting its clinical value for the management
of SBC patients, be it before or after diagnosis. The lack
of statistical significance for the three groups could be
due to the small sample size of 142 patients for this rare
skull-base tumor.
Fig. 1 Local control as a function of Sekhar scores for 142 chordoma patients treated with Proton Therapy
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That said we have to understand that both analyses
looked at the problem from two different perspectives - the
Sekhar group from a surgical and we from a radio-
oncological point of view. Comparing the two cohorts, we
realized they differed in some aspects (Table 6). In our co-
hort, there were fewer large tumors, less patients were
treated for recurrent disease and GTR was achieved in
fewer cases. Size of GTV was not recorded in the original
paper, but initial tumor size was very similar in the two co-
horts (TED of 3.3 vs. 3.4 cm). In both, there were many
tumors showing intradural invasion with a comparable
number of sites involved. The age of the patients in the
Sekhar et al. paper and our cohort was almost identical.
It is thus questionable if these differences could ac-
count for the lack of statistical significance in our ana-
lysis. To see if our cohort included any outliers we also
compared it to other cohorts, such as the Centre de pro-
tonthérapie Orsay-Curie [20] and Heidelberg patients
[21] as well as our older cohort from the publication in
2016 [9]. We did not observe major differences between
the various institutional cohorts (Table 7).
In our analysis, the most significant risk factors for LC
seem to be recurrence after prior treatment (surgery or
radiotherapy), the number of oncological surgeries
(more than two) as well as the extent of surgery in
regards to GTV (> 40 cc) and proximity to OAR
Table 5 Univariable Analysis (Log-rank)
Local recurrence Overall survival
HR (95% CI) p HR (95% CI) p
Age (years)
> 42.5 (=median) 0.91 (0.46–1.82) 0.80 2.74 (1.11–7.69) 0.03
Sekhar score
< 8 0.31 (0.09–1.03) 0.04 1.03 (0.34–2.64) 0.95
8–12 1.29 (0.62–2.66) 0.49 0.73 (0.31–1.75) 0.46
> 12 1.83 (0.82–4.06) 0.13 1.57 (0.51–4.04) 0.37
Number of sites involved
> 3 (= median) 0.91 (0.46–1.81) 0.79 0.90 (0.38–2.17) 0.81
Vascular involvement (number of vessels)
> 1 (= median) 1.90 (0.54–2.16) 0.82 0.80 (0.34–1.92) 0.61
≤ 2 vs > 2 1.00 (0.43–2.31) 0.99 1.12 (0.37–2.85) 0.83
Intradural invasion
yes vs. no 1.38 (0.42–4.57) 0.60 0.75 (0.25–3.20) 0.64
PT for recurrent disease
yes vs. no 3.19 (1.57–6.50) < 0.01 1.92 (0.68–4.73) 0.17
Number of oncological surgeries
> 1 (= median) 1.33 (0.67–2.64) 0.42 1.41 (0.60–3.45) 0.44
≤ 2 vs > 2 0.38 (0.17–0.85 0.01 0.28 (0.12–0.76) < 0.01
Maximum extent of surgery
GTR vs. STR or Biopsy 1.26 (0.38–4.11) 0.72 1.62 (0.26–5.67) 0.51
Surgical complications
yes vs. no 1.90 (0.94–3.81) 0.07 2.84 (1.20–6.98) 0.01
Gross tumor volume (cc)
> 26 (= median) 1.26 (0.63–2.50) 0.51 2.89 (1.13–8.85) 0.03
≤ 40 vs. > 40 2.34 (1.17–4.69) 0.01 0.19 (0.07–0.46) < 0.01
Brainstem compression before PT
yes vs. no 2.53 (1.27–5.01) < 0.01 1.44 (0.55–3.47) 0.43
OA compression before PT
yes vs. no 2.21 (1.02–4.76) 0.04 2.14 (0.76–5.29) 0.11
Brainstem or OA compression before PT
yes vs. no 2.46 (1.22–4.96) < 0.01 1.64 (0.69–3.95) 0.25
PT proton therapy, GTR gross total resection, STR subtotal resection, cc cm3, OA optic apparatus
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(compression of brain stem and optic apparatus) before
PBS-PT. There was a significant difference in LC and/or
OS after univariable analysis, which could make them
useful for treatment guidance. Recurrence after prior
treatment was already included in the SGSCC, whereas the
other three were not, since it is a preoperative grading sys-
tem. The question remains if a postoperative prognostic
scoring system including the above-mentioned prognostic
factors could be of clinical value. This is particularly rele-
vant because SBC patients should be managed by surgery
and adjuvant radiation therapy and a need for a holistic
scoring system, not limited to the pre-operative setting is
urgently needed.
The main limitations of this analysis are its retrospect-
ive nature and the fact that we looked at our cohort not
in the preoperative setting but after surgery before adju-
vant PBS-PT. As a result, some endpoints of the original
paper could not be included in our analysis. Addition-
ally, the scoring of the whole study cohort was not
performed by a neuroradiologist but by a radiation on-
cologist. Having said that, these data suggest that scoring
can be indeed performed by a radiation oncologist man-
aging routinely SBC patients.
Conclusions
Our assessment of the SGSCC for our patients treated
with PBS-PT showed a trend towards better outcome for
patients with lower scores as compared to those with
higher scores. This is probably an indicator that the scor-
ing system could be useful to guide treatment and patient
follow-up for SBC patients. However, this SGSCC score
can only be applied in the pre-operative and not post-
operative setting as advocated by the authors. It remains
to be determined if a postoperative scoring system, not
limited to but including compression of the OARs, pre-
PBS-PT tumor volume, should be computed.
Abbreviations
SBC: Skull-base Chordoma; SGSCC: Sekhar Grading System for Cranial
Chordomas; PBS-PT: Pencil beam scanning-proton therapy; PSI: Paul Scherrer
Institute; MRI: Magnetic resonance imaging; GTR: Gross total resection;
STR: Subtotal resection; EKNZ: Ethikkommission Nordwest- und
Zentralschweiz; TED: Tumor equivalent diameter; Gy: Gray; GyRBE: Gray-
relative biological effectiveness; SFUD: Single-field uniform dose;
IMPT: Intensity modulated proton therapy; LR: Local recurrence; DR: Distant
recurrence; LC: Local control; DC: Distant control; OS: Overall survival;
LRFS: Local recurrence-free survival; GTV: Gross tumor volume; OAR: Organ at
risk; BPSC: Basic Progression Scoring System for Patients with Skull Base
Chordoma; PFS: Progression-free survival; KPS: Karnofsky Prognostic score
Acknowledgements
A special thank you goes to Ulrike Kliebsch for her help and competent
support with this project.
Authors’ contributions
AH collected and analyzed the data including the MRI measurements and
wrote the manuscript. BB helped with data collection, performed the
statistical analysis. FA and AP checked and approved the MRI measurements.
DCW was a major contributor writing the manuscript. All other authors read
and approved the final manuscript.
Funding
Not applicable.
Availability of data and materials
The datasets used and/or analyzed during the current study are available
from the corresponding author on reasonable request.
Table 6 Comparison of the two cohorts
This study
(n = 142)
Sekhar
(n = 42)
Age (years) 42 (median) 41 (mean)
GTR (%) 13 36
Follow-up (months) 51 50
Local recurrence (%) 24 19
LC (%) 75 (at 5 y) 81 (at 1 y)
OS (%) 83 (at 5 y) 100 (at 1 y)
SGSCC Score
< 8 (%) 28 19
8 to 12 (%) 59 55
> 12 (%) 13 26
TED (cm) 3.4 (median) 3.3 (mean)
Number of sites involved 3 (median) 4.6 (mean)
Vascular involvement
(number of vessels)
1 (median) na
Intradural invasion (%) 87 73
Treatment for recurrence (%) 15 40
GTR gross total resection, LC local control, OS overall survival, SGSCC Sekhar
Grading System for Cranial Chordoma, TED tumor equivalent diameter
Table 7 Comparison with older cohorts
This study (n = 142) Weber 2016 (n = 151) Paris D’Orsay (n = 34) Heidelberg (n = 155)
Age (years) 42 43 (mean) 59 48
GTV (cc) 26 35 24 70 (PTV)
Treatment for recurrence (%) 15 36 44 35
GTR (%) 13 4 9 0
LC (%) 75 (at 5 y) 76 (at 5 y) 83 (at 3 y) 72 (at 5 y)
OS (%) 83 (at 5 y) 86 (at 5 y) 91 (at 3 y) 85 (at 5 y)
GTV (cc) gross tumor volume in cm3, GTR gross total resection, LC local control, OS overall survival
Hottinger et al. Radiation Oncology           (2020) 15:96 Page 7 of 8
Ethics approval and consent to participate
This analysis was approved by the Northwest and Central Switzerland Ethics
Committee (EKNZ 2018–00621) and conducted in accordance with
institutional guidelines and the principles of the Declaration of Helsinki and
its subsequent amendments [15].
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Author details
1Center for Proton Therapy, Paul Scherrer Institute, 5232 PSI West, Villigen,
Switzerland. 2Neuroradiology Department, Kantonsspital Baden, Baden,
Switzerland. 3Department of Physics, ETH Zürich, Zürich, Switzerland.
4Radiation Oncology Department, University Hospital of Bern, Bern,
Switzerland. 5Radiation Oncology Department, University Hospital of Zürich,
Zürich, Switzerland.
Received: 31 March 2020 Accepted: 22 April 2020
References
1. Smoll NR, Gautschi OP, Radovanovic I, Schaller K, Weber DC. Incidence and
relative survival of chordomas: the standardized mortality ratio and the
impact of chordomas on a population. Cancer. 2013;119:2029–37.
2. Healey JH, Lane JM. Chordoma: a critical review of diagnosis and treatment.
Orthop Clin North Am. 1989;20:417–26.
3. McMaster ML, Goldstein AM, Bromley CM, Ishibe N, Parry DM. Chordoma:
incidence and survival patterns in the United States, 1973-1995. Cancer
Causes Control. 2001;12:1–11.
4. Chugh R, Tawbi H, Lucas DR, Biermann JS, Schuetze SM, Baker LH.
Chordoma: the non-sarcoma primary bone tumor. Oncologist. 2007;12:
1344–50.
5. Kayani B, Sewell MD, Tan KA, Hanna SA, Williams R, Pollock R, et al.
Prognostic factors in the operative management of sacral chordomas.
World Neurosurg. 2015;84:1354–61.
6. Di Maio S, Temkin N, Ramanathan D, Sekhar LN. Current comprehensive
management of cranial base chordomas: 10-year meta.Analysis of
observational studies. J Neurosurg. 2011;115:1094–105.
7. Fuchs B, Dickey ID, Yaszemski MJ, Inwards CY, Sim FH. Operative
management of sacral chordoma. J Bone Joint Surg Am. 2005;87:2211–6.
8. Tzortzidis F, Elahi F, Wright DC, Temkin N, Natarajan SK, Sekhar LN. Patient
outcome at long-term follow-up after aggressive microsurgical resection of
cranial base chordomas. Neurosurgery. 2006;59:230–7.
9. Weber DC, et al. Long term outcomes of patients with skull-base low-grade
chondrosarcoma and chordoma patients treated with pencil beam
scanning proton therapy. Radiother Oncol. 2016;120:160–74.
10. Arman J, et al. Factors predicting recurrence after resection of Clival
Chordoma using variable surgical approaches and radiation modalities.
Neurodurgery. 2015;76:179–86.
11. Bohmann LE, et al. Skull Base Chordoma and Chondrosarcoma: influence of
clinical and demographic factors on prognosis: a SEER analysis. World
Neurosurg. 2014;82:806–14.
12. Zou MX, et al. Prognostic factors in Skull Base Chordoma: a systematic
literature review and meta-analysis. World Neurosurg. 2018;109:307–27.
13. Jun-Peng M, et al. Proposal and validation of a basic progression scoring
system for patients with Skull Base Chordoma. World Neurosurg. 2016;91:
409–18.
14. Brito da Silva H, Straus D, Barber JK, Rostomily R, Ferreira M, Sekhar LN.
Cranial Chordoma: a new preoperative grading system. Neurosurgery 2017;
0:1–13.
15. World Medical Association Declaration of Helsinki: ethical principles for
medical research involving human subjects. JAMA. 2013;310(20):2191–4.
16. Hindi N, et al. Imatinib in advanced chordoma: a retrospective case series
analysis. Eur J Cancer. 2015 Nov;51(17):2609–14.
17. Magnaghi P, et al. Afatinib is a new therapeutic approach in Chordoma
with a unique ability to target EGFR and Brachyury. Mol Cancer Ther. 2018
Mar;17(3):603–13.
18. Sanusi O, Arnaout O, Rahme RJ, Horbinski C, Chandler JP. Surgical Resection
and Adjuvant Radiation Therapy in the Treatment of Skull Base Chordomas.
World Neurosurg 2018;115:e13–21.
19. Yasuda M, Bresson D, Chibbaro S, Cornelius JF, Polivka M, Feuvret L, et al.
Chordomas of the skull base and cervical spine: clinical outcomes
associated with multimodal surgical resection combined with proton-beam
radiation in 40 patients. Neurosurg Rev. 2012;35:171–82.
20. Georges N, et al. Combination of photon and proton radiation therapy for
Chordomas and Chondrosarcomas of the Skull Base: the Centre de
Protonthérapie D’Orsay experience. Int J Radiation Oncology Biol Phys.
2001;51(2):392–8.
21. Uhl M, et al. Highly effective treatment of Skull Base Chordoma with carbon
ion irradiation using a raster scan technique in 155 patients: first long-term
results. Cancer. 2014;120:3410–7.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Hottinger et al. Radiation Oncology           (2020) 15:96 Page 8 of 8
